Neurodegenerative Market Forecast to 2013
Comprehensive Forecasts for Neurodegenerative Conditions
The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:
Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012.
The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.
Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients’ quality of life could see hundreds of millions — or even billions — of dollars in sales.
In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimer’s, Multiple Sclerosis and Parkinson’s markets.
Detailed Product Profiles
CEI’s veteran analysts examine 40 brands representing different classes and stages of development. The profiled products represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:
Drug history
Competitive and strategic positioning:
Current status of drug
Sales position within its class
Presence or strength of competition
Market growth opportunities:
Analysis combines new/current sales or clinical trial info with projections, predictions, insights
Analysis supported by sales projection charts, covering up to the next 7 years
Materiality charts, for 2007 and 2012
Charts containing market exclusivity and patent information for approved drugs
Clinical trial data tables to quickly show clinical detail:
Describes trial and why drug is in its current stage
Progress of drug
Analyses weigh the challenges and opportunities of each indication, class, and individual brand. Which brands will reap dividends and why? Whose sales are expected to drop? Which experimental therapies represent the next great medical breakthrough? Who will be the markets’ leaders in the next decade?
Give your brand team all the data it needs to make critical product decisions!
Products:
Profiled Brands in Alzheimer’s, Multiple Sclerosis and Parkinson’s
Alzheimer’s Disease
Anti-Amyloid Beta (Plaques)
Bapineuzumab / AAB-001
LY450139
LY2062430
ACC-001
Acetylcholinesterase Inhibitors
Aricept
Excelon
Razadyne
NMDA Antagonists
Namenda: also known as Ebixa in some EU countries
Ebixa: also known as Namenda in US
Other Alzheimer’s Therapies Targeting Neurotransmitters
Abilify
Dimebon
AZD3480 / TC-1734
SB 742457
Other Alzheimer’s Therapies
MEM1003
Tanakan
Avandia XR
Multiple Sclerosis (MS)
Immunomodulators
Copaxone
Fingolimod (FTY720)
BG-12 (Phase III)
Laquinimod (Phase III)
Teriflunomide
Oral Leustatin
Interferon Beta
Avonex
Rebif
Betaseron / Betaferon
Monoclonal antibodies
Rituxan
HuMax CD
Campath
Tysabri
SB689699
Other MS Therapies
Dirucotide (MBP8298)
Fampridine SR
Parkinson’s
Dopamineric drugs
Apokyn
Mirapex
Sinemet
Requip XL
Comtan / Stavelo
Other Drugs
Agilect / Azilect
ACP-103
Droxidopa
Companies:
More than 40 products from 25+ companies, including:
Eli Lilly
Pfizer
Wyeth
Bristol-Myers Squibb
Biogen Idec
Genentech
GlaxoSmithKline
Novartis
AstraZeneca
For more information kindly visit : http://www.bharatbook.com/Market-Research-Reports/Neurodegenerative-Market-Forecast-to-2013.html
Or
Contact us at:
Bharat Book Bureau
Tel: +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Thank you for reading this post. You can now Leave A Comment (0) or Leave A Trackback.
Post Info
This entry was posted on Friday, October 30th, 2009 and is filed under Uncategorized.You can follow any responses to this entry through the Comments Feed. You can Leave A Comment, or A Trackback.
Previous Post: Oncology Roadmap Brand Spending Benchmarks and Market Forecast to 2013 »
Next Post: Evolving Medical Information Call Centers through Performance Measurement and Process Improvement »
- The Evolving Global Meeting Management Strategy (PH111)
- Outcomes Based Pharmaceutical Pricing
- Diabetes Market Forecast to 2013
- Improve Market Research Impact
- Evolving Medical Information Call Centers through Performance Measurement and Process Improvement
- Neurodegenerative Market Forecast to 2013
- Oncology Roadmap Brand Spending Benchmarks and Market Forecast to 2013
- Driving Successful Pharma Brands Case Studies of Real Product Launches
- Thought Leader Fair Market Value Compensation Benchmarks and Procedures
- Key Opinion Leaders Relationship Management and Segmentation Data
Bharat Book Bureau